AIRSHIP
Acute Inflammation Resolution by Soluble Human Inhibitory Protein
| Coordinatore | CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Austria [AT] |
| Totale costo | 150˙000 € |
| EC contributo | 150˙000 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2011-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2013-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Organization address
address: Dr. Ignaz Seipel-Platz 2 contact info |
AT (WIEN) | hostInstitution | 150˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Acute inflammatory processes are associated with infections as well as autoimmune flares at the basis of a variety of human diseases. While the molecular components and the logic of pro-inflammatory program are relatively well understood, less is known about the molecular mechanism of resolution, governing the termination of inflammatory responses. In the course of carrying out the i-FIVE ERC grant project plan, we identified a novel, secreted, soluble enzyme as a negative regulator of pro-inflammatory immunity receptors. Here we propose a defined and focused set of measures aimed at obtaining solid evidence for therapeutic feasibility of this novel biological agent in resolving inflammatory processes as well as for the securing of intellectual property. The AIRSHIP workplan proposes to obtain enough purified, soluble, endotoxin-free, active and glycosylated protein material to execute two critical tests, one monitoring the inflammatory response in human cells, and one addressing beneficiary effects in a lung murine infection model. Armed with such a successful proof of concept package and having strategically positioned and secured our intellectual property rights we would be determined to embark into an ambitious commercialization initiative.'